share_log

NexImmune | 8-K: Current report

NexImmune | 8-K: Current report

NexImmune | 8-K：重大事件
美股sec公告 ·  07/19 16:06
Moomoo AI 已提取核心訊息
On July 19, 2024, NexImmune, a biotechnology company, held a special meeting of stockholders to vote on the liquidation and dissolution of the company. However, the meeting was adjourned without conducting any business to allow the company more time to explore alternative strategies that could maximize the value of its business and assets. The adjourned meeting is rescheduled for August 2, 2024, in a virtual format. Stockholders as of the record date, June 19, 2024, are entitled to vote and need not resubmit their proxy if they have already voted. NexImmune continues to solicit votes for the proposals outlined in the Proxy Statement, which is available on the SEC website. As of June 11, 2024, NexImmune had 1,371,051 shares of common stock and one share of Series A Preferred Stock issued and outstanding. The company's filings with the SEC, including its latest annual report and the definitive Proxy Statement, contain important information about the upcoming Special Meeting and the risks associated with the company's forward-looking statements.
On July 19, 2024, NexImmune, a biotechnology company, held a special meeting of stockholders to vote on the liquidation and dissolution of the company. However, the meeting was adjourned without conducting any business to allow the company more time to explore alternative strategies that could maximize the value of its business and assets. The adjourned meeting is rescheduled for August 2, 2024, in a virtual format. Stockholders as of the record date, June 19, 2024, are entitled to vote and need not resubmit their proxy if they have already voted. NexImmune continues to solicit votes for the proposals outlined in the Proxy Statement, which is available on the SEC website. As of June 11, 2024, NexImmune had 1,371,051 shares of common stock and one share of Series A Preferred Stock issued and outstanding. The company's filings with the SEC, including its latest annual report and the definitive Proxy Statement, contain important information about the upcoming Special Meeting and the risks associated with the company's forward-looking statements.
2024年7月19日，生物技術公司NexImmune召開了股東特別會議，就公司清算和解散進行投票。然而，會議因未進行任何業務而被延期，以使公司有更多時間探索可最大化其業務和資產價值的替代策略。延期後的會議定於2024年8月2日以虛擬方式重新安排。截至記錄日期6月19日，股東有權投票，無需重新提交委託書。NexImmune繼續徵求對代理聲明中概述的提案的投票，在SEC網站上可獲取該代理聲明。截至2024年6月11日，NexImmune已發行1,371,051股普通股和一股系列A優先股。該公司向SEC提交的文件，包括最新的年度報告和明確的代理聲明，包含關於即將召開的特別會議以及與公司前瞻性聲明相關的風險的重要信息。
2024年7月19日，生物技術公司NexImmune召開了股東特別會議，就公司清算和解散進行投票。然而，會議因未進行任何業務而被延期，以使公司有更多時間探索可最大化其業務和資產價值的替代策略。延期後的會議定於2024年8月2日以虛擬方式重新安排。截至記錄日期6月19日，股東有權投票，無需重新提交委託書。NexImmune繼續徵求對代理聲明中概述的提案的投票，在SEC網站上可獲取該代理聲明。截至2024年6月11日，NexImmune已發行1,371,051股普通股和一股系列A優先股。該公司向SEC提交的文件，包括最新的年度報告和明確的代理聲明，包含關於即將召開的特別會議以及與公司前瞻性聲明相關的風險的重要信息。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息